Annual Regional Biotechnology Conference
Angel Investing: Earning Your Wings
November 17, 2017
2:00- 5:00, followed by VIP Reception
PA Biotechnology Center, Room 100
We are pleased to announce registration is now open for the Regional Biotech Conference on Friday, November 17, 2017. Because there is a limited capacity for this event, we recommend advanced registration.
2017 was a big year for innovation and angel investing. More and more ideas are being turned into reality with the help of incubators, accelerator programs, and the heavy expansion of web-based collaborative platforms, with healthcare and pharma/biotech the largest growing sectors of angel investing. Angels are becoming more sophisticated, more organized and more integrated into the capital ecosystem that supports early-stage startups, and are staying involved longer than ever before, creating new collaborations and financing options that raise more money than initial and subsequent rounds. Join us on November 17 to hear keynote presentations from thought leading investors and entrepreneurs discuss the latest data and trends in startup investing!
Click here to register and reserve your seat: RBC REGISTRATION
Pre-registration conference fee is $100.00. Same day sign-up fee is $125.00
President & CEO, FORGE Life Science
Prior to FORGE, Lillian was VP of Translational Medicine at Kadmon Corporation. She was responsible for strategy and translation from early discovery through proof of concept in man. Throughout her career she has built from scratch, state-of-the-art technologies, drug discovery & development teams, and businesses at Stanford, Millennium Pharmaceuticals, Purdue Pharma, Aestus Therapeutics, and Kadmon. At Aestus, Chiang applied her own data mining algorithms to identify drug-repositioning assets to acquire and develop in a virtual pharma environment. Aestus’ first in-licensed product was successfully advanced from novel mechanism of action & therapeutic hypothesis to completion of phase 2A trial in 5 years and $5 M spend primarily funded by government grants. Chiang has a BS from MIT; her PhD from Wisconsin; completed her Post-Doc at Stanford University; and received her MBA from Wharton.
FORGE Life Science was founded on breakthrough discoveries made at Princeton University. FORGE’s vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broadspectrum treatment options.
Founder and Managing Partner, 1867 Capital Partners
Tom is founder and managing partner of 1867 Capital Partners which invests in early-stage life sciences, Fintech and tech-enabled business services firms. Tom is a serial entrepreneur, high-performance CEO and boardroom leader, and an experienced early-stage investor. He has led four successful exits – two public and two private firms – and led a successful NASDAQ IPO. Before founding 1867 Capital Partners, Tom and his executive teams delivered a 24-year 20.2% average annual return to investors. Most recently Tom was recruited to lead the turnaround, transformation and IPO of Fox Chase Bank. In the ten years that Fox Chase was a public company it produced the highest total investor return of any publicly-traded bank in Pennsylvania. Tom is chairman of the board of OrthogenRx, Inc. and BizEquity, Inc. He is a board member of Univest Corporation and Wealth Hub Solutions, Inc. He is past chairman of the Pennsylvania Bankers Association, past vice-chairman of government relations for the American Bankers Association, and chaired the Philadelphia Community Depository Institutions Advisory Counsel for the Federal Reserve Board of Governors. Tom is a two-time E&Y Entrepreneur of the Year finalist, a three-time winner of Future 50 recognizing the fastest growing firms in the region and was voted Most Admired CEO by the readers of the Philadelphia Business Journal.
Sanjay K. Sehgal
Founder, Managing Partner & CEO, East West Capital Partners
Mr. Sehgal brings over 22 years of global private equity experience, having led or co-led investments worth nearly $350 million of equity.
He is the Chairman of Seraxis, a stem cell research company focused on treating diabetes, operating out of the US and Singapore. He is also a Board member of LiPlasome Pharma ApS, Denmark – an oncology drug delivery company; and Braidlock Limited, a UK medtech company. He is also Senior Advisor to Visterra, Inc, a biotech spinout from MIT, with operations in Singapore. Sehgal was recently a Board Member and Chairman of the Audit Committee of an Australian-listed company, ITL Limited.
Sehgal was a Partner at Schroder Capital Partners (Asia), based out of Singapore and Hong Kong where he helped pioneer the entry of the Schroder private equity Funds’ into the Healthcare and Life Sciences domain and geographically into India. Seghal was an active Board member of private and listed companies in which the Schroder Funds’ invested. He was a member of the Investment Committee, for the Schroder Funds’ which had $725 million under management and was keenly involved in the negotiated deals in India, USA, Latin America, China, Australasia and southeast Asia. Prior to joining Schroder Capital Partners, Sehgal worked at LEK Consulting in London and Boston. Previously, he was a Member of Technical Staff at GTE Laboratories (now Verizon) in USA.
Seghal has a MBA in Finance and Management, with distinction, from The Wharton School, Philadelphia, PA; an MSc in Telecommunications from Columbia University, NY; and a Bachelors degree in Technology (Elec. Engg.), from the Indian Institute of Technology (IIT Bombay).
Seghal was elected as Hon. Secretary, Singapore Venture Capital & Private Equity Association for 2005 and as Hon. Treasurer in 2004.
Executive-in-Residence, Pappas Ventures
Peter Young is an experienced life science industry consultant and has been an executive-in-residence with Pappas Ventures since 2012. He leads the firm’s initiatives in translational medicine and is the Program Manager for the Wake Forest Technology Development Program. He also provides business development and due diligence support to the firm’s venture funds and portfolio companies.
Young has thirty-five years of experience in the pharmaceutical and biotech industry, spanning all areas of the business from sales representative to country-level general manager and CEO; and companies ranging from multinationals like Abbott and Glaxo to start-up biotechs. As Vice President and Therapy Area Head at Glaxo Wellcome in the mid-1990s, he led the global introduction of combination HIV therapy that revolutionized HIV treatment and quintupled Glaxo’s global HIV portfolio sales, while keying industry leadership on global treatment access. Peter has since served as CEO of two private start-up enterprises, a viral vector vaccine company that raised over $80 million in NIH HIV and biodefense vaccine grants, and a specialty pharmaceutical company he led to an exit via a strategic transaction.
Young currently serves on the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research, and is a member of the Long Island Bioscience Hub External Review Board. He was a past member of the BIO board, past Chairman of the North Carolina Biosciences Organization (NCBIO), and was a director of Memory Pharmaceuticals from 2004 until its sale to Roche in 2009. He has lived and worked in the US, Greece, the Middle East, Puerto Rico, New Zealand, and London. Young received his BA in History from Indiana University, and an MBA from IU Kelley School of Business.
Click here to register online: RBC REGISTRATION
Print and web advertising sponsorship opportunities are available. Please email email@example.com for more information.
Pre-registration conference fee is $100.00. Same day sign-up fee is $125.00
The event details are as follows:
Organization: Pennsylvania Biotechnology Center
Event Name: 2017 Regional Biotech Conference
Date(s): Nov 17 2017, 02:00 PM to 06:30 PM (includes VIP reception)
Location: Pennsylvania Biotechnology Center/Baruch S. Blumberg Institute
Click here for event information